INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Inotek Pharmaceuticals Corporation Invest...

Law Offices of Howard G. Smith announces an investigation on behalf of investors of Inotek Pharmaceuticals Corporation (“Inotek” or the “Company”) (NASDAQ: ITEK) concerning the Company and its officers’ potential violation of federal securities laws.

Inotek is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye in the United States.

On January 3, 2017, Inotek revealed that its Phase 3 trial for trabodenoson failed to reach its primary endpoint, despite prior representations by the Company regarding the efficacy of the drug and the likelihood of FDA approval. On this news, shares of Inotek fell over 70% on January 3, 2017, closing at just $1.75 per share.

If you purchased Inotek securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at [phone], toll-free at [phone], or by email to [e-mail], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170110006159/en/

Law Offices of Howard G. SmithHoward G. Smith, [e-mail]